Adhikari Saurav, Budhathoki Uttam, Thapa Panna
Kathmandu University, Drug Delivery Research Lab, Department of Pharmacy, Dhulikhel, Nepal.
Turk J Pharm Sci. 2022 Aug 31;19(4):422-430. doi: 10.4274/tjps.galenos.2021.57615.
Divalproex sodium (DS), being a hygroscopic drug, requires low humidity during product manufacturing. This study aims to develop a hygroscopicity controlled sustained release formulation of DS that can be manufactured in relatively high humid conditions in facilities lacking dehumidifiers.
This study focuses on the role of polyethylene glycol (PEG-8000) and hydroxypropyl methylcellulose (HPMC K100M) as polymers of choice to control hygroscopicity and retard release of DS using solid dispersion technique. In this study, homogeneous solid dispersions containing various ratios of PEG-8000, HPMC K100M, and DS were obtained melt granulation technique. Fifteen different solid dispersions were prepared based on Box-Behnken experimental design created in MiniTab software. The obtained solid dispersions were separately broken down into granules and their hygroscopic properties were determined moisture uptake studies. Granular solid dispersions were then compressed into tablets and their sustained release dissolution profiles were studied as the United States Pharmacopoeia (USP) monograph of DS extended-release tablets. Dissolution profiles of all fifteen formulations were then analyzed in Box-Behnken experimental design under MiniTab software to determine an optimized formulation having low hygroscopic properties as well as required multipoint drug release as USP monograph. The final optimized formulation was prepared and subjected to moisture uptake study to determine its hygroscopicity, dissolution study to determine drug release kinetics and fourier transform infrared (FTIR) and differential scanning calorimetry (DSC) analysis to determine molecular interactions between drug and polymers.
Optimized final formulation yielded granular solid dispersion with 28% less hygroscopicity compared to DS and tablets with an excellent release profile in accordance with USP monograph. FTIR and DSC analysis did not show any significant interaction between DS and components of the solid dispersion.
Optimized formulation from this study can be used to manufacture divalproex extended-release tablets inside facilities lacking dehumidifiers.
丙戊酸钠(DS)是一种吸湿性药物,在产品制造过程中需要低湿度环境。本研究旨在开发一种吸湿可控的DS缓释制剂,使其能够在缺乏除湿设备的设施中于相对高湿度条件下生产。
本研究聚焦于聚乙二醇(PEG - 8000)和羟丙基甲基纤维素(HPMC K100M)作为聚合物在控制DS吸湿性和延缓其释放方面的作用,采用固体分散技术。在本研究中,通过熔融制粒技术获得了含有不同比例PEG - 8000、HPMC K100M和DS的均匀固体分散体。基于Minitab软件创建的Box - Behnken实验设计制备了15种不同的固体分散体。将所得固体分散体分别制成颗粒,并通过吸湿研究测定其吸湿性能。然后将颗粒状固体分散体压制成片剂,并按照美国药典(USP)关于DS缓释片的专论研究其缓释溶出曲线。随后在Minitab软件的Box - Behnken实验设计下分析所有15种制剂的溶出曲线,以确定一种具有低吸湿性能以及符合USP专论要求的多点药物释放的优化制剂。制备最终优化制剂并进行吸湿研究以确定其吸湿性,进行溶出研究以确定药物释放动力学,并进行傅里叶变换红外光谱(FTIR)和差示扫描量热法(DSC)分析以确定药物与聚合物之间的分子相互作用。
优化后的最终制剂得到的颗粒状固体分散体与DS相比,吸湿性降低了28%,片剂具有符合USP专论的优异释放曲线。FTIR和DSC分析未显示DS与固体分散体组分之间有任何显著相互作用。
本研究中的优化制剂可用于在缺乏除湿设备的设施内生产丙戊酸缓释片。